These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 815561)

  • 1. Treatment of solid P815x2 murine mastocytoma with adriamycin (NSC-1231127): toxity limitations.
    Schenken LL; Poulakos L; Hagemann RF; Burholt D; Lesher S
    J Natl Cancer Inst; 1976 Mar; 56(3):683-5. PubMed ID: 815561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of local tumor growth with combined fractionated radiotherapeutic and chemotherapeutic regimens.
    Poulakos L; Schenken LL; Hagemann RF; Burholt DR; Lesher S
    J Natl Cancer Inst; 1975 May; 54(5):1103-5. PubMed ID: 805253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined-modality oncotherapy with cyclophosphamide (NSC-26271) and radiotherapy: control of murine mastocytoma.
    Schenken LL; Hagemann RF; Burholt DR; Lesher S
    J Natl Cancer Inst; 1976 Oct; 57(4):943-9. PubMed ID: 826650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responses of an experimental solid tumour to irradiation: A comparison of modes of fractionation.
    Schenken LL; Poulakos L; Hagemann RF
    Br J Cancer; 1975 Feb; 31(2):228-36. PubMed ID: 809050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adriamycin-induced inhibition of arachidonate incorporation into phospholipids of mastocytoma P815 cells.
    Kondakova IV; Vereschagina SV; Borunov EV
    Cancer Chemother Pharmacol; 1992; 31(1):79-80. PubMed ID: 1458564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary excretion of 5-hydroxyindoles as an indicator of in vivo growth of P815X2 mastocytoma.
    Raikow RB; Schenken LL; Lesher S
    Eur J Cancer (1965); 1976 Dec; 12(12):1011-5. PubMed ID: 827448
    [No Abstract]   [Full Text] [Related]  

  • 7. Proliferative character and growth modes of neoplastic disease as determinants of chemotherapeutic efficacy.
    Schenken LL
    Cancer Treat Rep; 1976 Dec; 60(12):1761-76. PubMed ID: 829040
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin.
    Balazsovits JA; Mayer LD; Bally MB; Cullis PR; McDonell M; Ginsberg RS; Falk RE
    Cancer Chemother Pharmacol; 1989; 23(2):81-6. PubMed ID: 2491964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. V. Spleen immunoreactivity and cell mediated cytotoxicity.
    Laatikainen A; Syrjänen K; Mäntyjärvi R; Tosi P
    Arch Geschwulstforsch; 1987; 57(4):265-74. PubMed ID: 3118852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A procedure for the quantitative separation of viable and non-viable P815X2 mastocytoma cells.
    Wilbur SM; Dettman GL
    J Immunol Methods; 1976; 11(3-4):213-23. PubMed ID: 819586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of L-histidinol on the susceptibility of P815 mastocytoma cells to selected anticancer drugs in vitro and in DBA/2J mice.
    Warrington RC; Cheng I; Fang WD
    J Natl Cancer Inst; 1987 Jun; 78(6):1177-83. PubMed ID: 3108563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. IV. Lymph node immunoreactivity and cell-mediated cytotoxicity.
    Laatikainen A; Syrjänen K; Mäntyjärvi R; Tosi P
    Neoplasma; 1987; 34(4):431-9. PubMed ID: 3116439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered immunologic responsiveness in mastocytoma-bearing mice.
    Kamo I; Patel C; Friedman H
    J Natl Cancer Inst; 1976 Feb; 56(2):333-8. PubMed ID: 815558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. III. Morphometric assessment of the dynamic changes in post-capillary venules as regulatory elements of lymphocyte recirculation in tumor-draining lymph nodes.
    Tosi P; Syrjänen K; Cintorino M; Mäntyjärvi R; Luzi P; Miracco C; Laatikainen A; Leoncini L; Santopietro R
    Arch Geschwulstforsch; 1987; 57(1):7-15. PubMed ID: 3105513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors.
    Corbett TH; Griswold DP; Mayo JG; Laster WR; Schabel FM
    Cancer Res; 1975 Jun; 35(6):1568-73. PubMed ID: 1131824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic activity of gallic acid against liver metastasis of mastocytoma cells P-815.
    Ohno T; Inoue M; Ogihara Y
    Anticancer Res; 2001; 21(6A):3875-80. PubMed ID: 11911262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple tumoricidal effector mechanisms induced by adriamycin.
    Salazar D; Cohen SA
    Cancer Res; 1984 Jun; 44(6):2561-6. PubMed ID: 6327018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
    Sirotnak FM; Otter GM; Schmid FA
    Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
    Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined adriamycin and hyperthermia treatment of a murine mammary carcinoma in vivo.
    Overgaard J
    Cancer Res; 1976 Sep; 36(9 pt.1):3077-81. PubMed ID: 975075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.